The most common side effects are nausea, vomiting, constipation, diarrhea and heartburn
What the Phase 2 Data Shows The retatrutide Phase 2 obesity trial (Jastreboff et al., New England Journal of Medicine , 2023) is the primary published source for quantifying the heart rate effect
In this article, well look at one example of that relationship, the risk of depression and suicidal ideation, acknowledging this is just that one example and the relationships between GLP-1s and other aspects of mental health and well-being may differ greatly
Notably, the median PA time of ~6 days (for cases needing extra review) means many patients wait well over a week to start treatment ( [5] )
Brown Adipose Tissue: A New Potential Target for Glucagon-like Peptide 1 Receptor Agonists in the Treatment of Obesity
This can be dangerous, as compounded medicines, like all medicines, should only be used under the supervision of a licensed healthcare provider